# Association of Bacille Calmette-Guérin (BCG), Adult Pneumococcal and Adult Seasonal Influenza Vaccines with Covid-19 Adjusted Mortality Rates in Level

## **4** European countries

#### Are there arguments for correlation and causation?

Joe Gallagher<sup>1</sup>, Chris Watson<sup>2</sup>, Mark Ledwidge<sup>\*1,3</sup>

<sup>1</sup>School of Medicine, UCD Conway Institute, University College Dublin, Dublin, Ireland.
<sup>2</sup>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, UK.
<sup>3</sup>Chronic Cardiovascular Disease Management Unit and Heart Failure Unit, St Vincent's Healthcare Group, Co. Dublin, Ireland

#### \*Correspondence:

Prof Mark Ledwidge School of Medicine, University College Dublin, Dublin, Ireland. **Email:** mark.ledwidge@ucd.ie

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### Abstract

#### Introduction

Non-specific effects of vaccines have gained increasing interest during the Covid-19 pandemic. In particular, population use of BCG vaccine has been associated with improved outcomes. This study sought to determine the association of population use of BCG, adult pneumococcal and adult seasonal influenza vaccination with Covid-19 mortality when adjusted for a number of confounding variables.

#### Methods:

Using publicly available data, mortality adjusted for the timeframe of crisis, population size and population characteristics was calculated. The primary analysis was the relationship between each of the day 15 and day 30 standardised mortality rates and BCG, adult pneumococcal and influenza vaccination scores using unadjusted measures and with adjustment for population structure and case fatality rates. Secondary analyses were measures of case increases and mortality increases from day 15 to day 30 for each of the relative vaccination scores. Finally, we also analysed the peak Z score reflecting increases in total mortality from historical averages reported by EuroMOMO (Euromomo.eu),

#### **Results:**

Following adjustment for the effects of population size, median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate, only BCG vaccination score remained significantly associated with Covid-19 mortality at day 30. In the best fit model, BCG vaccination score was associated with a 64% reduction in log(10) mortality per 10 million population (OR 0.362 reduction [95% CI 0.188 to 0.698]), following adjustment for population size, median age, density, urbanization, elderly dependency ratio, days to lockdown, yearly migration and case fatality rate.

#### Conclusion

BCG vaccine was associated with reduced mortality rates in level 4 countries while adult pneumococcal and adult seasonal influenza vaccines were not when adjusted for a number of confounding variables. A number of trials are ongoing to determine if BCG is protective against severe Covid-19 infection.

## Introduction:

Non-specific, "priming" effects of vaccines have rapidly gained interest recently during the Covid 19 pandemic. While Bacille Calmette-Guérin (BCG), pneumococcal, influenza and others vaccines have been associated with beneficial effects beyond those targeting the illness they are designed to prevent(1–5), considerable public interest has followed ecological studies suggesting that countries with universal BCG vaccination policies have lower mortality with Covid 19(6–9).

However, the studies suggesting beneficial effects of the BCG vaccine to date are limited in at least 4 important ways. First, countries have very specific timeframes in the Covid 19 outbreak, yet none of the mortality comparisons to date adjust for timeframe as well as population size. Second, the population structure differs considerably in the countries studied, resulting in confounding by factors such as population size, population density, urbanisation and elderly dependency ratio. Thirdly, the apparent case fatality rate is very different in study countries and, in addition to population structure factors mentioned above, is dependent on the case definition, testing strategy and availability of SARS-CoV-2testing, which has been different in the countries. Finally, documentation of Covid19 deaths in level 1-3 (Low and Middle Income) countries is limited because a high proportion of deaths occur at home without medical assistance and my not be accounted for properly in government records. Indeed, these concerns have led to the WHO issuing a scientific brief highlighting that is no evidence currently that the BCG vaccine protects people against infection with COVID-19 virus and that further study is required(10).

Accordingly, while the results of prospective studies are awaited, we investigated the association between adult influenza, pneumococcal and BCG vaccination rates and standardised Covid 19 mortality outcomes in 25 level 4 European countries, taking into account the important confounders described above.

#### Methods:

Using publicly available mortality data from the John's Hopkins Coronavirus Research Centre and demographic information presented on worldometers.info, we constructed curves of cumulative mortality adjusted for timeframe of crisis and population size, as previously described in a rapid response to an editorial on SARS-CoV-2testing and comparative international mortality rates[11a]. In order to standardise the timeframe, we designated the baseline (day 1) as the day that mortality rates exceeded 1 per 5 million population. We calculated the day 15 and day 30 mortality rate per 10 million population for each of the following 25 level 4 European countries Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Lithuania, Luxembourg, Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Kingdom. We also obtained recent data on population structure including population size, the median age (years), population density (persons/Km2), the proportion of population living in an urban setting, life-expectancy (years), the elderly dependency ratio (proportion of people over 65 years divided by the proportion aged 15-65) and net migration (expressed per 10 million population). In multivariable modelling we also included the case fatality rate on day 21 to account for differences in testing rates, testing strategy and case definition as well as the relative number of days between baseline (day 1) and lockdown.

In order to standardise the estimation of the proportion of the population covered with BCG vaccination, we generated a BCG vaccination score by dividing the median life expectancy by the total number of years that BCG vaccination was available and recommended for all children. We adjusted this calculation by multiplying with a measure of vaccination programme efficacy, using the most recent vaccination coverage rate for either BCG or universal childhood vaccination rates as appropriate. In the case of two countries that do not routinely recommend BCG vaccination and where few details were available (Iceland, Luxembourg) we used referenced estimates of the total population covered by BCG vaccination. Similarly, for pneumococcal vaccination, we generated a pneumococcal vaccination over the past decade using a variety of referenced sources in circumstances where uptake is considered relatively low in most European countries, despite recommendations for their use in over 65s and vulnerable populations. Finally, we created an influenza vaccination score as the proportion of older adults with seasonal influenza vaccination from most recent sources provided by the European Centre for Disease Control and other referenced reports.

The primary analysis of our report was the relationship between each of the day 15 and day 30 standardised mortality rates and BCG, pneumococcal and Influenza vaccination scores using unadjusted measures and with adjustment for population structure and case fatality rates. Secondary analyses were measures of case increases and mortality increases from day 15 to day 30 for each of the relative vaccination scores. Finally, we also analysed the peak Z score reflecting increases in total mortality from historical averages reported by EuroMOMO (Euromomo.eu), a European mortality monitoring activity, aiming to detect and measure excess deaths related to seasonal influenza, pandemics and other public health threats, supported by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO).

Primary and secondary outcomes were analysed using generalized linear modeling with a Poisson outcome distribution for adjusted mortality rates. Analyses were performed both with and without adjustment for the effects of population size, the median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate. Variables such as day 15 and day 30 mortality rates, case fatality rates, population size, population density and life expectancy, were not normally distributed across the countries and were log-transformed before inclusion in the generalized linear model. Nominal statistical significance was set at P<0.05 with Bonferroni correction for the 3 pairwise correlations involved in the primary analyses (three vaccination scores linked to day 30 mortality rates), meaning a P value of 0.05/3=0.0167 was considered statistically significant. Descriptive data are presented as either mean ± SD or median (25th: 75th percentile) for normally and non-normally distributed continuous variables, respectively. Frequencies and percentages (in parentheses) summarize categorical variables. Graphs were presented using GraphPad Prism v6 and statistical analysis was performed using the R statistical software package (Version 3.6.2, 2019-12-12, Copyright 2019 The R Foundation).

# Results

The population structure of the 25 countries are presented in Table 1.

Country	Population	Median age (years)	Over 65 years (%)	Life expectancy (years)	Population density (P/Km <sup>2</sup> )	Urban population proportion	Elderly Dependency Ratio	Yearly migration (%)
Austria	9006398	43.5	19.0	82.1	109	0.57	0.31	0.0057
Belgium	11589623	41.9	18.8	82.2	383	0.98	0.31	0.0044
Czechia	10708981	43.2	19.4	79.9	139	0.74	0.29	0.0018
Denmark	5792202	42.3	19.8	81.4	137	0.88	0.33	0.0035
Estonia	1326535	42.4	19.6	79.2	31	0.68	0.31	0.0007
Finland	5540720	43.1	21.7	82.5	18	0.86	0.35	0.0015
France	65273511	42.3	20.3	83.1	119	0.82	0.33	0.0022
Germany	83783942	45.7	21.5	81.9	240	0.76	0.35	0.0032
Greece	10423054	45.6	21.7	82.8	81	0.85	0.33	-0.0048
Hungary	9660351	43.3	19.2	77.3	107	0.72	0.28	-0.0025
Iceland	341243	37.5	14.8	83.5	3	0.94	0.23	0.0065
Ireland	4937786	38.2	13.9	82.8	72	0.63	0.22	0.0113
Italy	60461826	47.3	22.8	84.0	206	0.70	0.38	-0.0015
Lithuania	2722289	45.1	19.7	76.4	43	0.71	0.29	-0.0135
Luxembourg	625978	39.7	14.1	82.8	242	0.88	0.22	0.0166
Netherlands	17134872	43.3	18.8	82.8	508	0.93	0.30	0.0022
Norway	5421241	39.8	17.0	92.9	15	0.83	0.27	0.0079
Poland	37846611	41.7	17.5	79.3	124	0.60 0.24		-0.0011
Portugal	10196709	46.2	22.0	82.7	111	0.67	0.35	-0.0029
Slovakia	5459642	41.2	15.6	78.0	114	0.54	0.22	0.0005
Slovenia	2078938	44.5	19.6	81.9	103	0.55	0.29	0.0001
Spain	46754778	44.9	19.4	84.0	94	0.80	0.31	0.0004
Sweden	10099265	41.1	21.0	83.3	25	0.88	0.34	0.0063
Switzerland	8654622	43.1	18.6	84.3	219	0.74	0.29	0.0074
United Kingdom	67886011	40.5	18.4	81.8	281	0.83	0.31	0.0053
Median	9660351	43.1	19.4	82.5	111	0.76	0.31	0.0022
Quartile 1	5421241	41.2	18.4	81.4	72	0.68	0.28	0.0001
Quartile 3	17134872	44.5	20.3	83.1	206	0.86	0.33	0.0057

**TABLE 1** Population structure of the 25 countries included in the analysis, obtained fromworldometers.info, April 2020. Abbreviation: UK, United Kingdom.

The date of exceeding 1 SARS-CoV-2death per 5 million population, date of lockdown and cases, deaths and case fatality rates (CFR) on days 15 and 30 are presented in Table 2.

Country	Day 1*	Date of Lock-down	Days To Lock- down**	Cases / 10m day 15	Cases / 10m day 30	Deaths / 10m day 15	Deaths / 10m day 30	CFR day 15	CFR day 30	Δ Deaths / 10m day 15-30 ***	Δ Cases / 10m day 15-30 ***
Austria	16/03/2020	16/03/2020	0	11303	16205	142.12	478.55	0.013	0.030	336.43	490.21
Belgium	11/03/2020	18/03/2020	7	5380	23009	189.82	2604.92	0.035	0.113	2415.09	1762.96
Czechia	24/03/2020	16/03/2020	-8	4685	6711	82.17	196.10	0.018	0.029	113.92	202.63
Denmark	15/03/2020	11/03/2020	-4	4449	11241	132.94	516.21	0.030	0.046	383.27	679.19
Estonia	25/03/2020	13/03/2020	-12	8933	12099	180.92	346.77	0.020	0.029	165.85	316.61
Finland	25/03/2020	27/03/2020	2	4489	7932	72.19	319.45	0.016	0.040	247.26	344.36
France	07/03/2020	17/03/2020	10	2454	13857	103.26	1365.18	0.042	0.099	1261.92	1140.34
Germany	16/03/2020	23/03/2020	7	8571	16083	92.50	454.02	0.011	0.028	361.53	751.28
Greece	14/03/2020	23/03/2020	9	1109	2058	37.42	94.98	0.034	0.046	57.56	94.89
Hungary	20/03/2020	28/03/2020	8	645	1983	26.91	195.65	0.042	0.099	168.73	133.85
Iceland	21/03/2020	13/03/2020	-8	41525	51957	117.22	293.05	0.003	0.006	175.83	1043.24
Ireland	11/03/2020	14/03/2020	3	3684	16382	38.48	581.23	0.010	0.035	542.75	1269.80
Italy	27/02/2020	09/03/2020	11	2921	14306	209.39	1510.71	0.072	0.108	1301.32	1138.54
Lithuania	20/03/2020	16/03/2020	-4	2384	4768	33.06	128.57	0.014	0.027	95.51	238.40
Luxembourg	13/03/2020	18/03/2020	5	29250	52414	287.55	1054.35	0.010	0.020	766.80	2316.38
Netherlands	09/03/2020	16/03/2020	7	3245	11993	161.08	1311.94	0.050	0.109	1150.87	874.77
Norway	14/03/2020	12/03/2020	-2	7902	12180	47.96	247.18	0.006	0.020	199.22	427.76
Poland	23/03/2020	13/03/2020	-10	1166	2687	28.27	112.56	0.024	0.042	84.29	152.09
Portugal	19/03/2020	19/03/2020	0	9695	19305	241.25	673.75	0.025	0.035	432.49	961.00
Slovakia	06/04/2020	16/03/2020	-21	2196	2577	25.64	49.45	0.012	0.018	23.81	38.10
Slovenia	14/03/2020	16/03/2020	2	3410	5830	52.91	678.23	0.016	0.045	625.32	241.95
Spain	07/03/2020	14/03/2020	7	6153	29232	379.00	2853.40	0.062	0.098	2474.40	2307.94
Sweden	15/03/2020	NA	NA	3988	11333	144.56	1022.85	0.036	0.090	878.28	734.41
Switzerland	08/03/2020	17/03/2020	9	10162	25712	138.65	948.63	0.014	0.037	809.97	1555.01
UK	14/03/2020	23/03/2020	9	2876	13054	245.85	1919.25	0.085	0.147	1673.39	1017.87
Median	15/03/2020	16/03/2020	2.5	4449	12180	117.22	516.21	0.020	0.040	383.27	734.41
Quartile 1	11/03/2020	13/03/2020	-4	2876	6711	47.96	247.18	0.013	0.029	168.73	241.95
Quartile 2	20/03/2020	18/03/2020	7.25	8571	16382	180.92	1054.35	0.036	0.098	878.28	1138.54

**TABLE 2** Outcome data for the 25 countries included in the analysis, including cases, deaths, case fatality rates (CFR) and changes in deaths and cases between day 15 and day 30. Data obtained from worldometers.info, April 2020. \*Day 1 refers to the date that the country exceeded 1 death per 5 million population. \*\*The Days to Lockdown refers to the relative number of days from Day 1 to date of lock-down. \*\*\* Refers to the change in deaths and cases per 10 million population between days 15 and 30. Abbreviations: CFR Case Fataility Rate; UK, United Kingdom.

The BCG, pneumococcal and Influenza vaccination scores, datasources as well as the derivation values for BCG vaccination scores are presented in Table 3.

Country	Population Size *	Estimated Year BCG Introduced	Estimated Year BCG Stopped	Reported BCG VCR	National Childhood VCR	Life expectancy (Years)*	BCG Vacc Score**	PNEU MOCO CCAL Vacc Score	Influen za Vacc Score
Austria	9006398	1952 <sup>1</sup>	1990 <sup>1</sup>	0.98 <sup>1</sup>	-	82.05	0.454	0.34311	0.140 <sup>13</sup>
Belgium	11589623	1953 <sup>3</sup>	1989 <sup>1</sup>	-	0.97 <sup>2</sup>	82.17	0.425	0.64911	-
Czechia	10708981	1953 <sup>1</sup>	2010 <sup>1</sup>	0.80 <sup>1</sup>	-	79.85	0.571	0.61912	0.25014
Denmark	5792202	1946 <sup>1</sup>	1986 <sup>1</sup>	0.80 <sup>1</sup>	-	81.4	0.393	0.13711	0.470 <sup>14</sup>
Estonia	1326535	1953 <sup>3</sup>	Ongoing <sup>1</sup>	0.95 <sup>2</sup>	-	79.18	0.804	-	0.05015
Finland	5540720	1941 <sup>1</sup>	2006 <sup>1</sup>	0.95 <sup>4</sup>	-	82.48	0.749	0.10011	0.47014
France	65273511	1950 <sup>1</sup>	2007 <sup>1</sup>	0.79 <sup>4</sup>	-	83.13	0.542	0.28711	0.50015
Germany	83783942	1956 <sup>5</sup>	1998 <sup>1</sup>	-	0.95 <sup>2</sup>	81.88	0.487	0.70211	0.35014
Greece	10423054	1953 <sup>3</sup>	Ongoing <sup>1</sup>	0.88 <sup>6</sup>	-	82.8	0.712	0.42611	-
Hungary	9660351	1953 <sup>1</sup>	Ongoing <sup>1</sup>	0.99 <sup>2</sup>	-	77.31	0.858	0.56612	0.22014
Iceland	341243	1948 <sup>7</sup>	1950 <sup>7</sup>	-	-	83.52	0.041	0.48711	0.44014
Ireland	4937786	1950 <sup>1</sup>	2015 <sup>2</sup>	0.87 <sup>2</sup>	-	82.81	0.683	1.07311	0.68014
Italy	60461826	1970 <sup>1</sup>	2001 <sup>1</sup>	-	0.94 <sup>2</sup>	84.01	0.347	0.29811	0.52014
Lithuania	2722289	1953 <sup>3</sup>	Ongoing <sup>1</sup>	0.98 <sup>2</sup>	-	76.41	0.859	-	0.24014
Luxembourg	625978	-	-	-	-	82.79	0.590	-	0.38015
Netherlands	17134872	1953 <sup>3</sup>	1979 <sup>1</sup>		0.93 <sup>2</sup>	82.78	0.292	0.02611	0.58014
Norway	5421241	1947 <sup>9</sup>	2009 <sup>1</sup>	-	0.99 <sup>2</sup>	92.94	0.660	0.34411	0.55014
Poland	37846611	1955 <sup>1</sup>	Ongoing <sup>1</sup>	0.93 <sup>2</sup>		79.27	0.763	0.78612	0.07014
Portugal	10196709	1965 <sup>10</sup>	2015 <sup>10</sup>	0.92 <sup>2</sup>	-	82.65	0.557	0.20611	0.65014
Slovakia	5459642	1953 <sup>1</sup>	2012 <sup>1</sup>	0.98 <sup>2</sup>	-	78	0.754	0.64112	0.13014
Slovenia	2078938	1947 <sup>1</sup>	2005 <sup>1</sup>	0.97 <sup>2</sup>	-	81.85	0.687	-	0.10014
Spain	46754778	1965 <sup>1</sup>	1981 <sup>1</sup>	-	0.97 <sup>2</sup>	83.99	0.185	0.66111	0.56014
Sweden	10099265	1940 <sup>1</sup>	1975 <sup>1</sup>	-	0.98 <sup>2</sup>	83.33	0.412	0.43011	0.49014
Switzerland	8654622	1960 <sup>1</sup>	1987 <sup>1</sup>	-	0.94 <sup>2</sup>	84.25	0.301	0.17911	0.390
UK	67886011	1953 <sup>1</sup>	2005 <sup>1</sup>	-	0.93 <sup>2</sup>	81.77	0.591	0.21211	0.71014
Median	9660351	1953	2006	0.940	0.950	82.480	0.571	0.426	0.440
Quartile 1	5421241	1950	1990	0.873	0.940	81.400	0.412	0.212	0.230
Quartile 3	17134872	1954	2016	0.978	0.970	83.130	0.712	0.641	0.535

**TABLE 3** BCG, pneumococcal (PNEUMOCOCCAL) and influenza (Influenza) vaccination scores for the countries included in the analysis with referenced sources. \*Population and Life Expectancy data were obtained from Worldometers.info, May 2020. \*\*BCG Vacc Score was calculated by multiplying the estimated vaccination coverage rate (BCG if available or Dpt1/3 childhood vaccination coverage estimate if not) by the country's average life expectancy divided by the number of years BCG vaccination availability.

Abbreviations: BCG Bacille Calmette-Guérin; VCR, Vaccination Coverate Rate; PNEUMOCOCCAL, Pneumococcal Vaccination; Influenza, Influenza; UK United Kingdom. Vaccination Score references:

1 <u>http://www.bcgatlas.org</u>, updated 2017/2011; 2; <u>https://apps.who.int/immunization\_monitoring/globalsummary/</u>, average of reported data to 2018, using DPT1/3 as proxy for National Childhood VCR; 3 No data available, replaced with average of reported data for 25 countries; 4 <u>https://apps.who.int/immunization\_monitoring/globalsummary/</u>, average of reported data 1990-2000; 5 <u>http://www.bcgatlas.org</u>, average of East (commenced 1951) and West Germany (commenced 1961); 6 <u>https://apps.who.int/immunization\_monitoring/globalsummary/</u>, reported for neonates 2000; 7 Sigurdsson S. Tuberculosis in Iceland.

1976, Laeknabladid 2005 Jan;91(1):69-102, BCG Vacc Score is calculated from estimated 14,000 people vaccinated in Iceland by 1976; 8 Antonia D, Bussiere E, Guignon N et al. Vaccine Coverage of Pre-School Age Children In France in 2000. Eurosurveillance 2003;(8):139-144; 9 BCG vaccination reported mandatory from 1947 to 1995 referencing "Tuberkulosevaksinasjon – veileder for helsepersonell" published 09.04.2008, Norweigan Institute of Public Health; 10, Reported on the Portugese National Vaccination programme on http://venice.cineca.org/documents/portugal\_ip.pdf and vaccination shortages experienced post 2015 limiting coverage; 11 Fedson D, Nicolas-Spony L, Klemets P et al. Pneumococcal Polysaccharide Vaccination for Adults – New Perspectives for Europe. Expert Rev Vaccines 2011;10(8):1143-1167; 12 Mehmet Ceyhan, Ron Dagan, Abdullah Sayiner, et al. Surveillance of pneumococcal diseases in Central and Eastern Europe, Human Vaccines & Immunotherapeutics 2016; 12:8, 2124-2134; 13 Kunze U, Böhm G, Prager B, Groman E Influenza vaccination in Austria: Persistent resistance and ignorance to influenza prevention and control. Cent Eur J Public Health 2019, 27(2):127-130 | DOI: 10.21101/cejph.a5010; 14 European Centre for Disease Prevention and Control. Seasonal influenza vaccination and antiviral use in EU/EEA Member States – Overview of vaccine recommendations for 2017–2018 and vaccination coverage rates for 2015– 2016 and 2016–2017 influenza seasons. Stockholm: ECDC; 2018, https://www.ecdc.europa.eu/sites/default/files/documents/seasonalinfluenza-antiviral-use-2018.pdf; 15 OECD Data https://data.oecd.org/healthcare/influenza-vaccination-rates.htm; 16 Zürcher K, Zwahlen M, Berlin C et al. Trends in influenza vaccination uptake in Switzerland: Swiss Health Survey 2007 and 2012 Swiss Med Wkly. 2019;149:w14705



Mortality rates adjusted for timeframe and population size

**FIGURE 1** Day 15 and day 30 mortality per 10m population for the 25 countries included in the analysis, sorted in ascending order of day 30 mortality per 10m population. Data obtained from worldometers.info, April 2020

The unadjusted linear regression between log of deaths per 10 million on day 30 versus BCG, pneumococcal and influenza vaccination scores are presented in Figure 2A-C. Following adjustment for the effects of population size, median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate, BCG vaccination score remained significantly associated with Covid 19 mortality at day 30. In the best fit model, BCG vaccination score was associated with a 64% reduction in log(10) mortality per 10 million population (OR 0.362 reduction [95% CI 0.188 to 0.698]), following adjustment for population size, median age, density, urbanization, elderly dependency ratio, days to lockdown, yearly migration and case fatality rate. The log of case fatality rate (OR 2.526 [95% CI 1.147 to 5.563]) was the only other covariate that was significantly associated with Covid 19 mortality at day 30. There was no adjusted association between reported pneumococcal and influenza vaccination rates in older adults and Covid 19 mortality.

Similarly, as shown in Figure 3A-C, BCG vaccination score was significantly associated with day 15 log transformed mortality per 10 million population (HR 0.511 reduction [95% CI 0.277 to 0.943]), increase in cases between day 15 and day 30 (HR 0.398 reduction [95% CI 0.167 to 0.947]) and increase in mortality between day 15 and day 30 (HR 0.398 reduction [95% CI 0.167 to 0.947]). None of the other vaccination scores (PNEUMOCOCCAL or Influenza) were associated with these secondary outcomes in adjusted models. Finally, amongst those countries contributing total mortality data to the European Mortality Monitoring Centre, the relationship between BCG vaccination and peak Z-score remains significant, again with and without covariate adjustment.



**FIGURE 2A-C** Primary outcome data for the correlation between cumulative Covid 19 mortality per ten million population at day 30 and the following: BCG vaccination score (A), unadjusted P=0.0022; PNEUMOCOCCAL vaccination score (B), unadjusted P=0.24; Influenza vaccination score (C), unadjusted P=0.001. Following adjustment for the effects of population size, median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate, only BCG vaccination score remained significantly associated with Covid 19 mortality at day 30.



Abbreviations: BCG, Bacille Calmette-Guérin; PNEUMOCOCCAL, pneumococcal; Influenza, influenza.

**FIGURE 3A-C** Secondary outcome data for the 25 countries included in the analysis between BCG vaccination score and the following: day 15 mortality per 10 million population (A), univariate P=0.0009; increase in cases between day 15 and day 30 (B), univariate P=0.002; increase in mortality per 10 million population between day 15 and day 30 (C), univariate P=0.0065. The individual figures show P values following adjustment for population size, median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate. Abbreviations: BCG, Bacille Calmette-Guérin; PNEUMOCOCCAL, pneumococcal; Influenza, influenza.

## Discussion

This observational, ecological study amongst a series of 25 level 4 European countries suggests that previously reported associations between BCG vaccination and reduced mortality from COVID 19 remain after adjusting for a number of important confounding variables. Similarly, adjusted inverse associations between BCG vaccination and increase in cases and increase in deaths from day 15 to day 30 in the time-course of the outbreak were observed. The covariates used to adjust the relationship included population size, median age, population density, the proportion of population living in an urban setting, life-expectancy, the elderly dependency ratio (or proportion over 65 years), net migration, days from day 1 to lockdown and case-fatality rate. Conversely, associations were not observed with most recently available adult pneumococcal vaccine coverage or seasonal influenza vaccination in this setting with similar covariate adjustment. Prospective clinical studies on the potential role of BCG vaccination repurposed in the setting of Covid 19 will provide important and timely information for clinicians, patients and healthcare systems.

Studies suggesting that countries providing universal BCG vaccine coverage have decreased mortality with COVID 19(6–9) have been the source of wide media interest. However, there have been significant concerns about confounding factors and the lack of randomised controlled data to determine if there is a true causation between BCG vaccination and reduced mortality with COVID 19 (10). While this ecological study may be the first to evaluate BCG vaccination in models with standardisation of mortality rates for timeframe of the outbreak as well as population size, as well as incorporating extensive covariate adjustment related to population structure, the major limitation is that it demonstrates correlation but cannot definitively assign causation. There may be many other confounding variables, which could account for the relationship between BCG vaccination and mortality. Furthermore, it is well accepted that differences in recording mortality between countries have been reported which may affect numbers. Finally, the BCG vaccination score is an estimate of the population coverage with BCG and may not accurately reflect the true population vaccination.

Conversely, the extensive covariate adjustment as well as differential relationship between BCG and influenza/pneumococcal vaccination scores, may support the hypothesis that BCG vaccination is associated with protection from the severest consequences of Covid 19. There is a persistent relationship between BCG vaccination and a variety of mortality and morbidity measures, including peak standardised Z-scores reported for the pandemic. The present study builds on a growing body of evidence that BCG vaccination may be associated with decreased illness severity unrelated to mycobacterium infection. Many have been epidemiological studies looking at overall mortality rates

but others have looked at specific unrelated causes such as parasites(11), fungi(12) and bacteria(13) in humans and animals. A recent systematic review concluded that there is evidence with low to moderate risk of bias that BCG vaccination prevents respiratory infections (pneumonia and influenza) in children and the elderly(14) A number of trials are ongoing at present to elucidate the role of BCG in preventing severe COVID 19 with three reported in clinicaltrials.gov(15–17).

To date, the nature of non-specific effects with BCG has not been fully elucidated, yet there are a number of possible mechanisms of causation to explain the correlations described in our study. Vaccines with non-specific effects would induce reprogramming of the innate immune responses, a mechanism that clearly differs from the adaptive immunity induced by the antigen-specific responses to the vaccine. Also, since BCG is generally administered to children, any putative innate immune cell "priming" following BCG would, necessarily, be retained many years following vaccination, suggesting an epigenetic link. Interestingly, BCG vaccination has been shown to cause epigenetic changes in innate immune cells via histone-3-lysine-4 (H3K4) methylation [13], which can can augment human IFN and ISG responses to non-mycobacterium and even fungal infections. Therefore, the BCG "primed" innate immune system could counter the SARS-like coronavirus early IFN and ISG suppression, providing a more robust initial innate immune response to limit replication of SARS-CoV-2virus.[18]

Interestingly, a major distinguishing feature of SARS-like coronavirus infections (SARS-Cov-1, MERS and SARS-Cov-2) is their association with innate immune system dysregulation, especially of early host interferon (IFN) and interferon-sensing-gene (ISG) immune responses.[19,20] The early IFN repression in innate immune cells by SARS-Cov1 is in contrast to non-SARS coronaviruses (e.g. 229E and HKU1), which are responsible for milder, cold-like infections.[21] Recently, it was shown that early suppression of IFN and ISG responses by SARS-Cov1 and MERS in human epithelial cells is associated with epigenetic changes involving histone lysine methylation, as has been demonstrated.[20] Furthermore, epigenetic modification of H3K27 in human cells modulates ACE2 expression, the human receptor for SARS-like coronaviruses[22]. The genetic homology of SARS-Cov1 and SARS-Cov2, indicates that these epigenetic modifications of histone-3-lysine-27 may also feature in Covid 19.

The search for a vaccine to manage the SARS-CoV-2pandemic is a global healthcare priority because of high transmissibility and Covid19 mortality rates. However, following a small, non-human primate

study of the Oxford RNA vaccine, the world's largest producer of vaccines is in negotiation to dedicate its production capacity to this developmental vaccine for SARS-CoV-2. [23,24] However, this could limit normal childhood vaccination programmes despite risks of using novel technology platforms to treat the novel SARS-CoV-2 virus. While we await the results of prospective, randomised, controlled clinical studies on novel vaccines specific for SARS-CoV-2, recent clinical progress with known drugs such as remdesivir highlight the potential of repurposing known therapies to combat Covid-19(18). The present study suggests that ongoing, prospective clinical studies to determine if BCG vaccination reduces the severity of Covid-19 in vulnerable patients could provide important information on the potential for innate immune priming with BCG as an adjunct to other clinical strategies for protection against the worst consequences of SARS-Cov2.

# **Conclusion:**

The association of BCG and reduced mortality from Covid-19 was seen even after standardising mortality between level 4 European countries and adjusting for confounding variables relating to population structure. A similar association was not seen with adult influenza and pneumococcal vaccination. The results of prospective clinical studies on BCG vaccination as an adjunct to usual care in the setting of Covid-19 are awaited.

## **Conflicts of interest:**

None to declare

#### Funding:

No funding was received for this study

## **References**

- 1. Lund N, Andersen A, Hansen ASK, Jepsen FS, Barbosa A, Biering-Sørensen S, et al. The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial. Clin Infect Dis. 2015 Nov 15;61(10):1504–11.
- Aaby P, Martins CL, Garly M-L, Bale C, Andersen A, Rodrigues A, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ. 2010 Nov 30;341(nov30 2):c6495–c6495.
- de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin Infect Dis. 2015 Jun 1;60(11):1611–9.

- Lee YJ, Lee JY, Jang YH, Seo S-U, Chang J, Seong BL. Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine. Front Microbiol. 2018 Jan 31;9:83.
- 5. Madhi SA, Klugman KP, The Vaccine Trialist Group. A role for Streptococcus pneumoniae in virusassociated pneumonia. Nat Med. 2004 Aug;10(8):811–3.
- Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study [Internet]. Epidemiology; 2020 Mar [cited 2020 Apr 26]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.03.24.20042937
- Dayal D, Gupta S. Connecting BCG Vaccination and COVID-19: Additional Data [Internet]. Health Informatics; 2020 Apr [cited 2020 Apr 26]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.07.20053272
- Sala G, Miyakawa T. Association of BCG vaccination policy with prevalence and mortality of COVID-19 [Internet]. Epidemiology; 2020 Apr [cited 2020 Apr 26]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20048165
- Shet A, Ray D, Malavige N, Santosham M, Bar-Zeev N. Differential COVID-19-attributable mortality and BCG vaccine use in countries [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Apr [cited 2020 Apr 26]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.01.20049478
- 10. WHO. Bacille Calmette-Guérin (BCG) vaccination and COVID-19 Scientific Brief [Internet]. WHO. 2020. Available from: https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19
- 11. Berendsen ML, van Gijzel SW, Smits J, de Mast Q, Aaby P, Benn CS, et al. BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa. BMJ Glob Health. 2019 Nov;4(6):e001862.
- 12. Wout JW, Poell R, Furth R. The Role of BCG/PPD-Activated Macrophages in Resistance against Systemic Candidiasis in Mice. Scand J Immunol. 1992 Nov;36(5):713–20.
- 13. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LAB, Ifrim DC, Saeed S, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci. 2012 Oct 23;109(43):17537–42.
- 14. Soliman, Ramin. Does BCG vaccination protect against acute respiratory infections and COVID 19? A rapid review of current evidence [Internet]. Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence. 2020. Available from: https://www.cebm.net/covid-19/does-bcg-vaccination-protect-against-acute-respiratory-infections-and-covid-19-a-rapid-review-of-current-evidence/
- 15. Bonten, MJM. Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA). [Internet]. clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04328441.
- 16. Curtis Nigel. BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) [Internet]. clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT04327206
- 17. Cirillio, JD et al. BCG Vaccine for Health Care Workers as Defense Against COVID 19 (BADAS) [Internet]. clinicaltrials.gov. [cited 2020 May 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT04348370
- 18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 Preliminary Report. N Engl J Med. 2020 May 22;NEJMoa2007764.